CARDIOVASCULAR: ANGIOGRAPHYNoncontrast Magnetic Resonance Angiography in the Era of Nephrogenic Systemic Fibrosis and Gadolinium DepositionLim, Ruth P. MBBS, DMedSc, MS, FRANZCR∗,†; Hecht, Elizabeth M. MD‡; Desmond, Patricia M. MBBS, PhD, FRANZCR†,§Author Information From the ∗Department of Radiology, Austin Health, Heidelberg †Department of Radiology, The University of Melbourne, Parkville, Victoria, Australia ‡Department of Radiology, Columbia University Medical Center, New York, NY §Department of Radiology, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Received for publication April 27, 2020; accepted June 16, 2020. Correspondence to: Ruth P. Lim, MBBS, DMedSc, MS, FRANZCR, Department of Radiology, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia (e-mail: [email protected]). Ruth P. Lim has grant funding from Boehringer Ingelheim (paid to her institution) not related to the subject of this article. The authors declare no other conflict of interest. Journal of Computer Assisted Tomography: 1/2 2021 - Volume 45 - Issue 1 - p 37-51 doi: 10.1097/RCT.0000000000001074 Buy Metrics Abstract Gadolinium-based contrast agents for clinical magnetic resonance imaging are overall safe. However, the discovery of nephrogenic systemic fibrosis in patients with severe renal impairment and gadolinium deposition in patients receiving contrast have generated developments in contrast-free imaging of the vasculature, that is, noncontrast magnetic resonance angiography. This article presents an update on noncontrast magnetic resonance angiography techniques, with comparison to other imaging alternatives. Potential benefits and challenges to implementation, and evidence to date for various clinical applications are discussed. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.